- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02753868
Acute Effects of Intradialytic Exercise on Cardiovascular Function in Hemodialysis Patients (ACE-HD)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Patients with kidney failure requiring hemodialysis (HD) treatment die at excessively high rates, despite advances in HD techniques and pharmacological therapies. This indicates additional therapeutic strategies are needed. Intradialytic exercise (IDEX, exercise during HD treatment) represents a low-cost, easy to administer treatment strategy that could potentially improve cardiovascular function, physical function and quality of life. However, nephrologists rarely counsel their patients to increase their physical activity levels or to exercise during HD treatment, in part due to a lack of understanding of IDEX knowledge.
Providing more robust evidence for the safety and effectiveness of IDEX, as well as evaluating the impact of exercising early vs late in the treatment, could help improve adoption of exercise training as a standard practice in HD clinics.
Therefore, investigators plan to examine the impact of IDEX and its timing during treatment (1st vs 3rd hour) on blood pressure and adverse symptoms in HD patients. The proposed study also includes various cardiovascular measures to allow deeper mechanistic understanding of cardiovascular physiology with IDEX. Such understanding will significantly advance the field and lead to improved therapeutic approaches, including exercise training, which may help mediate the deleterious effects of renal failure.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Urbana, Illinois, Stati Uniti, 61801
- University of Illinois at Urbana-Champaign
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Receiving hemodialysis treatment three times per week, on hemodialysis for greater than three months, receive medical clearance from a Nephrologists
Exclusion Criteria:
- Patients with established contraindications to exercise including lower-limb amputation, advanced chronic obstructive pulmonary disease and decompensated chronic heart failure.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Standard Hemodialysis
Participants will be monitored during their normal hemodialysis treatment with no intervention administered
|
Participants will receive a standard hemodialysis treatment during the study period
|
Sperimentale: Hemodialysis with Exercise (1-st hr)
Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
|
Participants will receive a standard hemodialysis treatment during the study period
Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
|
Sperimentale: Hemodialysis with Exercise (3-rd hr)
Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment
|
Participants will receive a standard hemodialysis treatment during the study period
Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Serial change in brachial blood pressure (mmHg) from start to end of a dialysis treatment
Lasso di tempo: Every 15 minutes throughout each dialysis treatment (approximately 4 hours)
|
Systolic and diastolic blood pressure will be measured using an automated blood pressure cuff attached to the clinic dialysis machine
|
Every 15 minutes throughout each dialysis treatment (approximately 4 hours)
|
Changes in cardiac output (mL/min) measured by thoracic impedance technique
Lasso di tempo: Continous throughout a dialysis treatment (approximately 4 hours)
|
Cardiac output will be estimated continuously using thoracic impedance with electrodes placed around the chest.
|
Continous throughout a dialysis treatment (approximately 4 hours)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Changes in total peripheral resistance estimated by peripheral blood pressure via a finger plethysmography and cardiac output via thoracic impedance (Task Force Monitor)
Lasso di tempo: Continuous throughout each dialysis treatment (approximately 4 hours) for three dialysis sessions that are separated by a week
|
A finger cuff will be placed around the non-dialyzing finger and will measure the change in peripheral blood pressure from successive beats continuously.
Total peripheral resistance will be estimated using measured cardiac output and peripheral blood pressure.
|
Continuous throughout each dialysis treatment (approximately 4 hours) for three dialysis sessions that are separated by a week
|
Hypotensive event assessment measured by a symptom questionnaire
Lasso di tempo: Throughout and up to 5 hours after completion of a dialysis treatment
|
The presence of hypotensive-relating intradialytic symptoms including nausea, dizziness and cramping will be recorded.
|
Throughout and up to 5 hours after completion of a dialysis treatment
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Kenneth Wilund, PhD, University of Illinois at Urbana-Champaign
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 15691
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Hemodialysis treatment
-
XeltisReclutamentoMalattia renale allo stadio terminaleSpagna, Italia, Belgio, Lettonia, Portogallo, Germania, Grecia, Regno Unito, Polonia
-
Reistone Biopharma Company LimitedCompletato
-
Hill-RomCompletato
-
Ohio State UniversityReclutamentoGenitorialità | Disturbi mentali nell'adolescenza | Adolescente - Problema emotivoStati Uniti
-
National Institute on Aging (NIA)SconosciutoDemenza | Problemi di comportamentoStati Uniti
-
University of GlasgowCompletatoMorbo di Crohn | Modifica dieteticaRegno Unito
-
University of MichiganWallace H Coulter Center for Translational ResearchCompletato
-
University of WashingtonCompletatoSchizofrenia | Disordine bipolare | Grave malattia mentale
-
Wake Forest University Health SciencesDuke University; University of RochesterCompletatoSuicidio | Genitorialità | Autoefficacia | Angoscia; MaternoStati Uniti
-
Memorial Sloan Kettering Cancer CenterTerminatoLe famiglie o i parenti prossimi dei pazienti trattati presso MSKCC per carcinomi a cellule squamose non cutanei del | Tratto aerodigestivo superioreStati Uniti